ym 2

SYM 2081 is a specific kainate receptor agonist with an IC50 value of 35 nM for [3H]-kainate binding. SYM 2081 depolarizes the muscle and reduces the EPSP amplitude.

mGlu1-selective antagonist

metabotropic glutamate receptor type 1 (mGlu1) antagonist

Selective mGlu1 antagonist

inhibitor of the reverse mode of Na+ Ca2+ exchange (NCX)

Competitive inhibitor of secretory phospholipase A2 (sPLA2)

YM 218 is a novel, potent, selective antagonist of nonpeptide vasopressin V1A receptor.

YM 212 is a biochemical.

YM 22508 is a biochemical.

YM 26567-1 is a biochemical.

YM 298198 Hydrochloride is a non-competitive antagonist with high affinity and selectivity for mGlu1 receptors (Ki = 19 nM). YM 298198 Hydrochloride is inactive at other mGlu receptor subtypes (mGlu2-7), ionotropic receptors and glutamate transporters (IC50 > 10 μM). It inhibits glutamate-induced IP production more potently than CPCCOEt (IC50 values are 16 nM and 6.3 μM respectively).

FG-2216 (YM-311) is a potent HIF-prolyl hydroxylase inhibitor for the PDH2 enzyme (IC50: 3.9 uM); orally bioavailable and induced reversible and significant Epo induction in vivo.

YM-430 is a β1 adrenergic receptor antagonist and a calcium channel antagonist. YM430 could be both an antianginal and antihypertensive agent. YM430 (10(-8)-10(-6) M) inhibited 3,4-diaminopyridine-induced rhythmic contractions with an IC50 value of 59.2 n

YM-543, a sodium-glucose transporter 2 (SGLT-2) inhibitor, is used potentially for the treatment of type 2 diabetes.

Ciwujianoside B (acanthopanax senticosides B) is the main component of Acanthopanax, can relieve fatigue, enhance memory, and improve human cognition.

YM-440 is a novel hypoglycemic agent, an insulin sensitizer, that may be used for the treatment of type 2 diabetes mellitus by reducing glucose 6-phosphatase activity in obese Zucker rats and inhibiting liver glucose output through gluconeogenesis.

YM-58483 (BTP2) is a specific and effective inhibitor of CRAC channels and subsequent Ca2+ signals.

Conivaptan hydrochloride (Vaprisol) is an orally active vasopressin V2 and V1A receptor antagonist, used in the therapy of hypervolemic hyponatremia and euvolemic.

YM-543, also known as ASP-543, is a selective SGLT2 inhibitor. Sodium-glucose cotransporter 2 (SGLT2) is a specifically expressed transporter in the kidney that plays an important role in renal glucose reabsorption, and its inhibition may present a novel therapeutic strategy for treating diabetes. YM543 potently and selectively inhibited mouse and human SGLT2 activities at nanomolar ranges. In vivo single oral administration of YM543 dose-dependently and significantly reduced blood glucose levels and improved glucose tolerance with a concomitant increase in urinary glucose excretion in KK Ay type 2 diabetic mice, effects that were sustained even after 12 h.

YM-1, a stable and soluble analog of MKT-077, is an orally active inhibitor of Hsp70 that induces cell death in HeLa cells and elevates the levels of p53 and p21 proteins [1] [2].

Minodronic acid(YM-529) is a P2X2 3 receptor antagonist with anticancer activity, directly or indirectly inhibiting the proliferation of cancer cells and inducing apoptosis. Minodronic acid has been shown to inhibit the metastasis of various types of cancer cells.Minodronic-acid has been used in the study of osteoporosis.